A Case Report on Scleroderma: A Diagnostic Dilema
Ch. K. V. L. S. N. Anjana Male *
Department of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Atmakuru, Mangalagiri-522503, A.P, India.
Hari Chandana Varikallu
Department of Pharmacy Practice, Nirmala College of Pharmacy, Atmakuru, Mangalagiri-522503, A.P, India.
Tirumalasetty Sai Swapna
Department of Pharmacy Practice, Nirmala College of Pharmacy, Atmakuru, Mangalagiri-522503, A.P, India.
N. Dileep
Department of Pharmacology, Nirmala College of Pharmacy, Atmakuru, Mangalagiri, India.
S. Hemanth Durga Prasad
Department of Pharmaceutical Analysis, Nirmala College of Pharmacy, Atmakuru, Mangalagiri, India.
Sarath Nalla
Department of Pharmacy Supervisor, Alcami Corporation, Wilmington, NC, 28411, USA.
*Author to whom correspondence should be addressed.
Abstract
Scleroderma is a rare heterogenous group of autoimmune fibrosing disorder that mainly exists in two forms; localized scleroderma (LS) and systemic sclerosis (SSc). It involves thickening of the skin at fingers region extending from proximal to metacarpophalangeal joints. The diagnostic criteria of scleroderma include past history of patient, symptoms of patient, serology, and skin biopsy. The morbidity and mortality are much worse for SSc with the patients are at risk for life threatening lung, heart and other visceral organ fibrosis and vasculopathy. There is no drug that can cure or stop scleroderma over fibrosis, but certain drugs regulate the symptoms associated with it and boost the patient's quality of life, particularly steroidal creams that help alleviate swelling, joint pain, loosen tight skin; blood pressure drugs that dilate blood vessels; immunosuppressive agents. If the disease is severe amputation is necessary.
Keywords: Localized scleroderma, systemic sclerosis, vasculopathy, morbidity, mortality, over fibrosis, amputation